ArticleCureus2025
Characterizing Musculoskeletal and Neurological Toxicities Associated With the BPaLM Regimen: A Clinical Evaluation of Arthralgia and Peripheral Neuropathy in Patients With Multidrug-Resistant Tuberculosis (MDR-TB).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMusculoskeletal and neurological toxicities are common side effects of the BPaLM (bedaquiline, pretomanid, linezolid, and moxifloxacin) regimen, an emerging treatment for multidrug-resistant tuberculosis (MDR-TB). These toxicities, particularly arthralgia and peripheral neuropathy, can significantly impair the quality of life of patients undergoing treatment. Despite the promising therapeutic benefits of the BPaLM regimen, the prevalence and severity of these side effects remain underexplored. Understanding these toxicities is crucial to improving patient management strategies and ensuring better treatment adherence.
objectiveThis study aims to determine how common and severe musculoskeletal and neurological toxicities, particularly arthralgia and peripheral neuropathy, are among MDR-TB patients treated with the BPaLM regimen. MATERIALS AND
methodsThis prospective observational study was conducted at the Programmatic Management of Drug-Resistant Tuberculosis in Mardan Medical Complex between January 2024 and April 2025. Patients with MDR-TB undergoing treatment with the BPaLM regimen were monitored for musculoskeletal and neurological toxicities, specifically arthralgia and peripheral neuropathy. Clinical evaluations included assessing the onset, severity, and impact of joint pain and nerve damage, as well as evaluating the effectiveness of pain management and physical therapy interventions. Data collection included demographic information, comorbidities, and baseline physical activity levels. Statistical analysis was performed using SPSS Statistics version 26 (IBM Corp. Released 2019. IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp.), Python (Python Software Foundation, Beaverton, OR, USA), and R 4.4.5 (R Foundation for Statistical Computing, Vienna, Austria) to identify significant predictors of toxicity severity through descriptive statistics, chi-square tests, and decision tree modeling. Kaplan-Meier survival analysis was also conducted to assess the relationship between toxicity severity and treatment outcomes.
resultsAmong the 44 MDR-TB patients, 35 (79.54%) experienced mild to moderate arthralgia, with knee pain being most common (34, 77.27%). Peripheral neuropathy was reported in 26 (59.09%) patients, with the lower limbs (20, 45.45%) being most affected. Kaplan-Meier survival analysis revealed a significant difference in survival times based on the severity of arthralgia and peripheral neuropathy, with more severe symptoms correlating with reduced survival duration.
conclusionsThe findings underscore the importance of early identification, regular monitoring, and personalized management strategies to mitigate the burden of these toxicities and enhance patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.